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Received November 19, 2013; accepted March 4, 2014AbstractBackground: A greater policy of emphasis on the early detection and treatment of breast cancer is prevalent among developed countries. To raise
the screening performance with a potentially decreased mortality rate, it is crucial to evaluate and analyze the screening outcome after
implementation. We report the clinical outcome of an 8-year nationwide mammography screening in Taiwan to help share our statistical in-
formation on breast screening worldwide, especially in Asia.
Methods: Taiwan has provided nationwide, free, biennial mammographic screening since 2004. A total of 2,392,789 consecutive screening
mammography examinations were performed during this study period for women aged 50e69 years (2006e2009) and 45e69 years (from
December 2009 onwards). The screening covers 33.2% of the target population in the most recent 2 years. The workload of every screening
radiologist, the overall recall rate, positive predictive value (PPV1), cancer detection rate (CDR), cancer incidence rate (CIR) from the screening,
1-year interval cancer, sensitivity, and specificity of the screening mammography are calculated, and compared with the American College of
Radiology (ACR) recommendation level and/or those of other screening mammographic series.
Results: The CDRs (%) and CIRs (%) increased from 3.94e4.08 and 4.80e5.04 to 4.71e5.04 and 5.71 after 2009, implying a high occurrence of
breast cancer in the younger age group of 45e49 years. The recall rates (9.3e10.0%) in this review are within the ACR recommendation range
(<10%) and the PPV1 has also reached the ACR recommended level (>5%) in the most recent 2 years. The improvement of the screening
performance may be attributed to our peer auditing review and education program. The sensitivity of our screening mammography is slightly
lower than that of the ACR recommended level (>85%), which is still comparable to the results of the Vermont area in the USA. Although the
workload (screenees/screeners) for every radiologist each year has increased from 150 in 2004 to 1360 in 2012, it does not seem to worsen the
quality outcome of this screening program.
Conclusion: From the outcome review of this national mammography screening, there is still room to ameliorate our performance through
comprehensive and continued education, to improve the competence of cancer detection and decrease false negative (FN) cases.
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Breast cancer is the most frequent cancer among women in
both developing and developed countries.1,2 Screening
mammography contributes to the substantial decrease of 6% in
breast cancer mortality, to 63% through early detection.3,4
Mortality increases in regions without early detection pro-
grams.5 Even for women in their 40s, screening mammography
was reported to efficiently reduce breast cancer mortality by
29%.6 Despite the fact that correlation of screening and mor-
tality is still debatable,7 a greater emphasis on the early detection
and treatment of breast cancer is prevalent among developed
countries.8 To raise the screening performance and potentially
decrease the mortality rate, it is crucial to evaluate and analyze
the screening outcome after implementation.9 Thereafter, we
report the clinical outcome [including positive predictive value
(PPV1), recall rate, cancer detection rate (CDR), early CDR,
sensitivity, and specificity] of an 8-year nationwide mammog-
raphy screening in Taiwan, to help share our statistical infor-
mation on breast screening worldwide, especially in Asia.
2. Methods2.1. Strategy of screening mammographySince 2004, a nationwide, free, biennial screening
mammography program has been offered for asymptomatic
women aged 50e69 years (before December 2009) and aged
45e69 years thereafter. For the convenience of screenees and
to increase the percentage coverage of participants, screening
mobile vans have also been used since 2007. Four views of
bilateral breasts in craniocaudal and mediolateral oblique
projections are the standard of our screening mammography.
Assessments are based on the Breast Imaging Reporting and
Data Systems (BI-RADS) established by the American Col-
lege of Radiology (ACR). In that system, categories 0, 4, and 5
are considered as positive assessments, representing either
requiring further study or increasing risk of malignancy. Cat-
egories 1, 2, and 3 are considered as negative assessments,
with requirement of a short follow up for the latter.10
To be qualified to attend the screening mammograms, all
board-certified radiologists and radiographers are asked to
attend a mammogram-interpretation or quality control edu-
cation program yearly. The former are also required to have
interpreted at least 1000 mammograms within 2 years.2.2. Definitions10True positive (TP) is tissue diagnosis of cancer within 1 year
after a positive examination (BI-RADS Category 0, 4, or 5 for
screening). False negative (FN) or interval cancer is tissue
diagnosis of cancer within 1 year of a negative examination
(BI-RADS Category 1 or 2 for screening, BI-RADS Category
1, 2, or 3 for diagnostic). Recall rate is reported as the per-
centage of positive interpretation (BI-RADS Category 0, 4, or
5; ACR recommended level to be <10%). PPV1 is the per-
centage of all positive screening examinations (BI-RADSCategories 0, 4, and 5) that result in a tissue diagnosis of cancer
within 1 year (ACR recommended level to be >5%). CDR from
screening is the number of cancers correctly detected/1000
patients examined on mammography (¼number of TP/number
of screening). Cancer incidence rate (CIR) from screening is
the number of cancers diagnosed from screening mammog-
raphy in 1 year [¼(number of TP þ number of FN)/number of
screening]. Sensitivity [TP/(TP þ FN)] is the probability of
detecting a cancer when a cancer exists or the number of can-
cers diagnosed after being identified at mammography in a
population within 1 year of the imaging examination, divided
by all cancers present in that population in the same time period
(ACR recommended level to be >85%). Specificity [TN/
(TN þ FP)] is the probability of interpreting an examination as
negative when cancer does not exist, or the number of true
negative mammograms in a population divided by all actual
negative cases (those for which there is no tissue diagnosis of
cancer within 1 year of the mammogram) in the population
(ACR recommended level to be >90%).2.3. Data collectionThe study was approved by the Institutional Review Board
at Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
and was performed according to the Declaration of Helsinki
principles. We collected data from the results of a free,
nationwide population-based mammography-screening pro-
gram funded and coordinated by Taiwan's Bureau of Health
Promotion (received on May 2012) and National Cancer
Registry. As the population of the participant women in the
first 2 years (2004 and 2005) was small (<100,000) and/or was
contaminated with symptomatic patients, we excluded the data
from these 2 years for later analysis.2.4. Statistical analysisAs the latest data (after 2010) of FN from the National
Cancer Registry is lacking at the start of this study, we re-
ported the numbers of screening, recall rate, PPV1, and CDR
(TP) data from the years 2004e2012, and the CIRs, 1 year
interval cancer (FN), sensitivity, and specificity from the years
2004 to 2010. Due to the size of the observations, the standard
error was small, and thus there was little need to test statistical
significance.
3. Results
Since the initiation of the screening program, the enrolled
mammographic units in our country increased from 102 units in
2004 to 195 units in 2012, including 68 mobile vans. The digital
mammographic system (CR or DR) was adopted at around 20%,
initially to reach >95% in 2012 (163 DR, 86 CR, and 11 screen-
film combinations). A total of 2,473,608 consecutive mammo-
graphic examinations for breast cancer screening were per-
formed between 2004 and 2012 and 2,392,789 between 2006
and 2012. The target population had increased from 17,272
women in 2004 to 670,528 in 2012. In the years 2011 and 2012,
Fig. 1. The numbers of screening units, radiologists, and radiographers who
participated in the screening mammography in Taiwan from 2004 to 2012.
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receiving screening mammography was 15.3% and 17.9%,
respectively. In other words, for a biennial screening program,
the adjusted coverage had reached 33.2% of the target popula-
tion in the most recent 2 years. For a corresponding service with
increasing participants, the number of qualified screening radi-
ographers and radiologists also progressively increased from
165 and 115, respectively, in 2004, to 857 and 493, respectively,
in 2012 (Fig. 1). The presumed average workload (participant
women/screening radiologists) for every radiologist was 150
in 2004, 486 in 2005, 512 in 2006, 521 in 2007, 611 in 2008,
843 in 2009, 1417 in 2010, 1215 in 2011, and 1360 in 2012.
In this study, the overall recall rates of screening
mammography in Taiwan after 2006 are between 9.28 and
10.0, which is within the ACR recommendation level. The
PPV1 values, albeit slightly <5% (4.10e4.88%) in the initial
years, reached the ACR recommended range in the latest 2
years (5.00% and 5.16%). The CDRs and CIRs of the screening
mammography were 3.94e4.39/1000 women and 4.80e5.04/
1000 women, respectively, for participants aged 50e69 years
before 2010; these increased to 4.71e5.04/1000 women and
5.71/1000 women following the enrollment of younger women
(aged 45e49 years). The percentage of early cancer in this
screening increased from 15.7% in 2004 to around 40% in
these years. The 1-year interval cancer rates ranged from 0.73/
1000 to 1.12/1000 screening women. The overall sensitivitiesTable 1
The clinical outcome of the screening mammography in Taiwan from 2004 to 201
Year RR (%) PPV1 (%) CDR (%) ECDR (%)
2004 10.3 5.2 5.38 15.7
2005 11.9 3.4 4.02 20.2
2006 9.8 4.1 4.03 18.3
2007 9.3 4.4 4.08 19.8
2008 9.9 4.4 4.39 30.3
2009 9.6 4.1 3.94 36.4
2010 9.7 4.9 4.71 41.7
2011 10.0 5.0 5.04 39.7
2012 9.6 5.2 4.96 39.9
CDR ¼ cancer detection rate; CIR ¼ cancer incidence rate from screening; ECDR
number of recall; RR ¼ recall rate; TP ¼ true positive; 1 y ICR ¼ 1st year intervin our screening mammography after 2006 ranged from 79.6%
to 87.0%, and the specificities ranged from 90.5% to 91.1%.
All of the above data are summarized in Table 1.
4. Discussion
The major goal of a screening mammography is to detect
occult breast cancer with an acceptable range of recommen-
dations for false positives, by raising both the CDR and
sensitivity. The influencing factors of CDR vary and include,
but are not limited to, social, economic, culture, race, and the
improvement of diagnostic modalities.11 In this retrospective
study, we found a trend of increase in the CDR and CIR from
the screening mammography after 2009, when younger
women (45e49 years old) were enrolled. This may be due to
the fact that breast cancer occurs in younger patients in
Taiwan. Mammography is of benefit for cancer detection in
young women with even higher breast density.
The recall rate in a screening examination is defined as the
percentage of screening studies for which further work-up is
recommended. A wide range of recall rates (1e15%) has been
reported for screening mammography in the literature.11,12 A
high recall rate means that screening program resources are
probably used inefficiently and women undergo unnecessary
follow-up procedures, although a low recall rate can potentially
result in lower rates of detecting incident breast cancers. The
recall rates of screeningmammography in Taiwan since 2005 are
between 9.28% and 10.0%, which is within the ACR recom-
mended range. Moreover, through the peer audit and education
programs, we find some extreme cases (i.e., recall rate >15% or
<5%) have been gradually eliminated in recent years.12
Recent publications have also used PPV1 as one of the
primary indicators of the quality of screening mammography
programs.11,13,14 PPV1 has been generally thought to represent
the “necessary balance” between sensitivity and specificity.
Low PPV1 usually indicates a high percentage of unnecessary
recall, which increases additional medical cost and a patient's
anxiety. However, a high PPV1 may still miss a certain
number of potentially detectable cancers if sensitivity is not
incorporated into the analysis. The PPV1 in our series reached
the ACR recommendation level of 5% in recent years.
Sensitivity is simplified as the probability of detecting a
cancer when a cancer exists on the film. Hence, high quality2.
CIR (%) 1 y ICR (%) Sensitivity (%) Specificity (%)
6.25 0.97 86.1 90.1
4.91 1.01 81.9 88.4
4.80 0.85 84.0 90.6
4.90 0.91 83.2 91.1
5.04 0.73 87.0 90.5
4.95 1.12 79.6 90.7
5.71 1.1 82.6 90.8
d d d d
d d d d
¼ early cancer detection rate; FN ¼ false negative; PPV1 ¼ number of TP/
al cancer rate.
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avoid FNs contribute to identifying the existing cancer. In a
recent study, Hofvind et al15 reported that the sensitivity of
final assessment for a 2-year follow-up was 83.3% for a single
reading in Vermont (USA) and 90.7% for a double reading in
Norway with the interval cancer (FN) of 1-year follow-up of
0.8/1000 and 1.2/1000 screening women, respectively. The
sensitivity and 1-year interval cancer in our series are
79.6e87.0% and 0.73e1.12/1000 screening women, respec-
tively. This is comparable with the results of Vermont area for
a single reading study.
The workload (screening women/screening radiologists) of
the screening program in Taiwan has increased from 150 in
2004 to >1200 in 2010e2012. The increased workload does
not seem to worsen the screening quality, including the in-
dicators of recall rate, PPV1, CDR, incidence rate, sensitivity,
and specificity. The increase of early CDRs is partly due to the
reduction of contamination of symptomatic patients which
occurred in the early years. It is also due to the improvement of
interpretation accuracy, which may be attributed to more ra-
diologists willing to be full-time breast imaging professionals
in recent years in Taiwan, and/or the successful education
programs feedback from the peer auditing system.13 To ach-
ieve higher sensitivity while lowering false positive rates,
further studies are needed to elucidate the interrelationships
between training, experience, workload, and performance
measures.16
The main strength of the present study is to assess the
screening mammography outcome by the use of a national
representative sample. Limitations of this study include
several variables that may affect the result, e.g., age, breast
density, asymptomatic or symptomatic, and prevalence (initial
screen) or incidence (subsequent screen). Risk factors have not
been analyzed due to data limitation provided from the Bureau
of Health Promotion. Further analyses are needed to better
interpret the results and trends of mammography screening.9
In conclusion, the medical audit data of screening
mammography in Taiwan in recent years has reached the
recommendation of ACR levels, except the screening sensi-
tivity, which is slightly lower but comparable with that of
Vermont's area in the USA. From the outcome review of this
national mammography screening, there is still room to
ameliorate our performance through comprehensive and
continued education, to improve the competence of cancer
detection and decrease FN cases.
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